A Randomized, Double-Blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-Term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease

Protocol No
GI-TAKEDA-VICTRIVA
Staff Member
Poonam Beniwal-Patel
Phase
III
Summary

This project is being done to see if the combination of Vedolizumab and Upadacitinib is safe and effective for treating patients with moderately to severely active Crohn's Disease and how the combination compares to the use of Vedolizumab alone reducing the symptoms of Crohn's Disease
Objective
Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
Study Sites
Froedtert Hospital
Status
OPEN TO ACCRUAL
Categories
Inflammatory Bowel Disease, Digestive System
ClinicalTrials.gov
https://www.clinicaltrials.gov/study/NCT06227910